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Abstract
Background: Immunity to food antigens (gliadin, cow's milk proteins) is in the centre of the
attention of modern medicine focused on the prevention of diseases, prevention which is based on
the use of appropriate restriction diet. Detection of the enhanced levels of the immune reactions
to antigen(s) present in food is from this point of view of great importance because there are
reports that some of health disturbances, like celiac disease (CD) and some premalignant
conditions, like monoclonal gammopathy of undetermined significance (MGUS), were vanished
after the appropriate restriction diets.
It is well known that gliadin is toxic to small bowel mucosa of relatively small population of
genetically predisposed individuals, who under this toxic action develop celiac disease (CD). As the
quantity of immunogenic gliadin could vary between different wheat species, the first aim of this
work was to determine the percentage of immunogenic gliadin in ten bread wheat cultivars and in
three commercially grown durum wheat cultivars. The second part of the study was initiated by
results of previous publication, reporting that sera of some of multiple myeloma (MM) patients
showed the presence of elevated levels of anti-gliadin IgA, without the enhanced levels of anti-
gliadin IgG antibodies, determined with commercial ELISA test. It was designed to assess is it
possible to reveal is there any hidden, especially anti-gliadin IgG immunoreactivity, in serum of
mentioned group of patients. For this purpose we tested MM patients sera, as well as celiac disease
(CD) patients sera for the immunoreaction with the native gliadin isolated from wheat species used
for bread and pasta making in corresponding geographic region.
Published: 31 May 2009
BMC Immunology 2009, 10:32 doi:10.1186/1471-2172-10-32
Received: 5 October 2008
Accepted: 31 May 2009
This article is available from: http://www.biomedcentral.com/1471-2172/10/32
© 2009 Konic-Ristic et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Immunology 2009, 10:32 http://www.biomedcentral.com/1471-2172/10/32
Page 2 of 7
(page number not for citation purposes)
Results: Gliadin was isolated from wheat flour by two step 60% ehanolic extraction. Its content
was determined by commercial R5 Mendez Elisa using PWG gliadin as the standard. Results
obtained showed that immunogenic gliadin content varies between 50.4 and 65.4 mg/g in bread
wheat cultivars and between 20 and 25.6 mg/g in durum wheat cultivars.
Anti-gliadin IgA and IgG immunoreactivity of patients' sera in (IU/ml) was firstly determined by
commercial diagnostic Binding Site ELISA test, and then additionally by non-commercial ELISA
tests, using standardized ethanol wheat extracts -gliadin as the antigen.
In both patients groups IgA immunoreactivity to gliadin from different cultivars was almost
homogenous and in correlation with results from commercial test (except for one patient with
IgA(λ) myeloma, they were more then five times higher). But, results for IgG immunoreactivity
were more frequently inhomogeneous, and especially for few MM patients, they were more then
five times higher and did not correlate with results obtained using Binding Site test.
Conclusion:  Results obtained showed different content of immunogenic gliadin epitopes in
various species of wheat.
They also point for new effort to elucidate is there a need to develop new standard antigen, the 
representative mixture of gliadin isolated from local wheat species used for bread production in 
corresponding geographic region for ELISA diagnostic tests.
Background
It is well known that gliadin is directly or indirectly
through immune mediated reactions, toxic to small bowel
mucosa of relatively small population of genetically pre-
disposed individuals who under this toxic action develop
celiac disease (CD). These patients need to eat food with-
out gluten, i.e., they need to be on gluten free diet (GFD).
Therefore very reliable tests are needed to determine is the
content of gliadin really below the accepted value (20 mg/
kg). As gliadin isolated from various species used as the
antigen may have different immunogenicity [1] that fact
could be a problem in the immunological tests used for
determination of gliadin content in food; i.e., results may
greatly depend on the origin and type of gliadin that was
used for calibration. In the aim to overcome this analytical
problem, "prolamin working group" developed a PWG
gliadin which represents protein fraction soluble in 60%
ethanol from the mixture of twenty-eight wheat cultivars
grown in Great Britain, France and Germany [1-6]. This
gliadin is recommended for use as the standard antigen in
immunological techniques for determination of gluten
content in food.
At the same time, it was very important to standardize
anti-gliadin antibodies that should be used in immuno-
logical tests for determination of gliadin content. In the
recent time few monoclonal or polyclonal anti-gliadin
antibodies were developed. Commercial kits often used
polyclonal antibodies developed against wheat gliadin, or
a monoclonal antibody made against ω-gliadins from the
Australian wheat cultivar 'Timgalen'. There were also
other antibodies developed in different laboratories such
as monoclonal antibody PN3, raised against a synthetic
peptide equivalent to the amino acids 31–49 of α-gliadin,
i.e. the sequence of toxic peptide of α-gliadin, which has
been shown to cause mucosal damage to the small bowel
of celiac patients [7,8]. The other polyclonal rabbit anti-
gliadin antibody made for the same proposes was pre-
pared against α-gliadin, isolated from the 'Kanzler' and
other German wheat cultivars. At the present time the
greatest attention has monoclonal antibody R5, devel-
oped against a secalin extract, which recognizes the poten-
tial celiac-toxic epitope QQPFP, which occurs repeatedly
in α-, γ- and ω-gliadins, hordeins and secalins, of wheat,
barley and rye to a similar degree. Applied in a sandwich
ELISA, this antibody showed identical calibration curves
for PWG- and Sigma-gliadin [6]. This antibody is now rec-
ommended by Codex Alimentarius [9,10] as an antibody
which has to be used in sandwich ELISA method for deter-
mination of gluten content in gluten free food. Today
there are commercial kits available for determination of
gluten content, that include R5 antibody as anti-gliadin
antibody and PWG gliadin for calibration (Ridascreen, R-
Biopharm, Germany).
The most toxic α-gliadin, mainly from the 6D genome of
wheat, is the major contributor in both activating the
adaptive immune response and the innate immune
response. Tetraploid wheat (T. durum) do not contain the
D genome. This wheat is hence already devoid of the
known immunogenic sequences of α-gliadins [11]. Mol-
berg et al. [12] reported that several wheat lacking the D
genome also lack the immunodominant 33-mer, but, they
did not extend their conclusion to all durum wheat.BMC Immunology 2009, 10:32 http://www.biomedcentral.com/1471-2172/10/32
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Therefore the first aim of this work was to determine the
percentage of immunogenic gliadin isolated from ten
bread wheat cultivars and three durum wheat cultivars
grown commercially in Serbia and neighbouring coun-
tries.
Testing sera for IgA or IgG immunoreactivity to gliadin is
usually one of the first steps in the complex process of
diagnosing gluten intolerance, because it is well known
that antibodies to native gliadin sequences are present in
patients with celiac disease. This, second part of the study,
was based on results of previous publication reporting
that sera of some of multiple myeloma (MM) patients
showed the presence of elevated levels of anti-gliadin IgA-
without the enhanced levels of anti-gliadin IgG immu-
noglobulins, determined on commercial ELISA test. It was
designed to assess is it possible to reveal is there any hid-
den, especially anti-gliadin IgG immunoreactivity, in
serum of mentioned group of patients. For this purpose
we tested MM patients' sera as well as celiac disease (CD)
patients' sera for the antigliadin immunoreactivity using
commercial ELISA test (Binding Site, Birmingham U.K),
as well as home made ELISA tests using commercially
available gliadin (alcohol soluble protein fraction from
crude gliadin products of Sigma, and the native gliadin
isolated from wheat species used from bread making in
corresponding geographic region as the antigen.
Results
Gliadin in ethanolic extract of wheat cultivars was
assessed on the basis of its immunoreactivity with mono-
clonal antibody R5, using PWG gliadin as the standard.
Some differences in the content of gliadin regarding vari-
ous wheat cultivars and their total protein contents could
be seen on Table 1. Investigated non-bread wheat culti-
vars: B, Z and D are with the approximately three time
lower content of immunogenic gliadin epitopes then cul-
tivars S, R and P which are used for bread production.
Fifteen patients with histopathologically confirmed celiac
disease were included in investigation: all of them were
not on gluten-free diet (GFD).
Results obtained analyzing fifteen CD patients' sera before
GFD, using commercial BS test, presented on Figure 1.,
showed the enhanced levels of anti-gliadin IgA and IgG
immunity in seven and nine patients respectively. Data pre-
sented, showed that IgA immunoractyivity of CD patient's
sera with gliadin isolated from tested wheat was in 3
Table 1: Gliadin content in thirteen different wheat cultivars.
No Wheat cultivar Wheat species Total gliadin mg/ml extract of 
wheat determined on the basis 
of R5
Gliadin content in 
wheat (mg/g)
Protein content in 
wheat(%)
Gliadin content/
Protein content(%)
1 R bread 3.27 65.4 11.4 57.4
2 Z bread 2.825 56.5 13.8 40.94
3 K bread 2.64 52.8 12.8 41.25
4 D durum 1.28 25.6 11.2 22.86
5 Zi durum 1 20 11.2 17.86
6 P bread 3.24 64.8 11.6 55.86
7 Pa bread 2.76 55.2 12 46
8 So bread 2.88 57.6 13.4 42.99
9 S bread 3.54 70.8 12 59
10 B durum 1 20 11.2 17.86
11 T bread 2.88 57.6 12 48
12 Lj bread 2.1 42 12 35
13 E bread 2.52 50.4 9.6 52.5BMC Immunology 2009, 10:32 http://www.biomedcentral.com/1471-2172/10/32
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patients more than three times higher than that obtained
on BS commercial test, revealing that 10/15 CD patients
had the enhanced serum antigliadin IgA antibodies.
It could be also seen that IgG immunoractivity of patient's
sera with gliadin isolated from tested wheat and crude
Sigma gliadin was in six patients more than three times
higher than that obtained on BS commercial test, reveal-
ing that almost all analysed CD patients' sera had the
enhanced levels serum antigliadin IgG antibodies.
The modest increase in IgA antigliadin antibodies were
found by BS test in three MM patients' sera, as it could be
seen on Figure 2. More then four times higher IgA immu-
noreactivity with gliadin isolated from local wheat was
found in one patient with IgA(λ) myeloma. While the
enhanced IgG immunity to gliadin in BS test was observed
in one from sixteen myeloma patients, more then five
times higher reactivity then that on commercial BS test
was found in additional four MM patients' sera on tested
wheat gliadin. It must be noted that two out from these
IgA and IgG immunoreactivity of celiac patients sera to gliadin of diiferent wheat cultivars Figure 1
IgA and IgG immunoreactivity of celiac patients sera to gliadin of diiferent wheat cultivars.
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IgA and IgG immunoreactivity of multiple myeloma patients sera with gliadin from diiferent wheat cultivar Figure 2
IgA and IgG immunoreactivity of multiple myeloma patients sera with gliadin from diiferent wheat cultivar.
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four patients' sera did not show the enhancement in the
IgG reaction with Sigma gliadin.
Discussion
Immunity to food antigens (gliadin, cow's milk proteins,
CMP) is in the centre of the attention of modern medicine
[13] focused on the prevention of diseases, prevention
which is based on the use of only appropriate restriction
diet. Detection of the enhanced levels of the immune reac-
tions in host, to antigen(s) present in food is from this
point of view of great importance because some of prema-
lignant conditions like monoclonal gammopathy of
undetermined significance (MGUS), disappeared after the
appropriate restriction diets: GFD diet [14] and CMP free
diet [15]. Thus detecting the enhanced immunity to some
of proteins present in food in people with some of immu-
nological health disturbances must be followed by more
detailed examination of immunogenic antigens in order
to prevent some more serious diseases like NHL, or MM.
It is well known that immunomediated toxicity of gliadin
is present in relatively small population of genetically pre-
disposed individuals, with class II human leukocyte anti-
gens HLA-DQ2 or -DQ8 which are found in nearly all
celiac patients. Non-HLA genes clearly may play a role in
celiac disease as well. The immunologic response to glu-
ten includes antibody reactivity to gluten proteins and the
autoantigen TG2, CD4+ T cell reactivity to gluten,
increased number of intraepithelial CD8+ T cells, NK
cells, and elevated levels of a number of cytokines and
chemokines [16]
In recent papers an increase in the incidence of certain
cancers among celiac disease patients, including non-
Hodgkin lymphoma, enteropathy-associated T-cell lym-
phoma, small intestinal adenocarcinoma, and esophageal
and oropharyngeal squamous carcinoma was reported,
together with the data that strict adherence to gluten-free
diet has been found to be effective at reducing the risk of
some malignancies [17]. The presence of anti-gliadin and
of anti-tTG imunoreactivity was found in patients with
multiple myeloma too [13], as well as the anti- CMP
(results not shown).
Results obtained in this work using monoclonal antibody
R5, clearly show that three of investigated wheat cultivars:
B, Zi and D are with the approximately three time lower
immunogenic content of gliadin then cultivars S, R and P.
They are in accordance with the already published data
that tetraploid wheat T. durum do not contain the D
genome, are hence already devoid of the known immuno-
genic sequences of α-gliadins [11]. They are also along
with similar data that there is various content of immuno-
genic gliadin in some of wheat cultivars grown in EU
countries [6].
In both patients groups IgA immunoreactivity to gliadin
from different cultivars was almost homogenous and in
correlation with results from commercial test (exept for
one patient with IgA(λ) myeloma). But, results for IgG
immunoreactivity were more frequently inhomogeneous,
and especially for few MM patients they were increased
and did not correlate with results obtained using Binding
Site test.
Regarding durum wheat immunogenicity our results
showed lower levels of humoral immunoreactivity to
durum wheat gliadins than to bread wheat gliadin in CD
patients and open an interesting area for further research
that can elucidate whether observed differences in immu-
nogenicity can be confirmed using peptic-tryptic gliadin
digest or deaminated gliadin, as the antigen [18]. But it
must be noticed that in three myeloma patients the anti-
gliadin immunity was preferentially pronounced on glia-
din from one tested durum wheat Zi, in relation to Sigma
gliadin.
This set up the question is there a need to develop new
standard antigen, the representative mixture of gliadin
isolated from wheat species used for bread and pasta pro-
duction in corresponding geographic region for ELISA
diagnostic tests.
Conclusion
Results obtained showed that there is different content of
immunogenic gliadin epitopes in various species of
wheat. They also point for new effort to elucidate whether
more reliable data on the existence of immunoreactivity
to wheat proteins in some people would be provided by
testing their sera for the immunoreaction with gliadin
from ethanolic extract of local wheat cultivars used for
bread making in the appropriate geographic region.
Methods
Plant material
The experimental material consisted of ten bread (P, R, E,
So, Lj, S, T, Z, Pa) and three durum (D, Zi, B) wheat cul-
tivars developed and commercially grown in Serbia and
neighbour countries. Grain samples of the bread and
durum wheat cultivars were collected in 2006 from plants
grown in field-trials at the Center for Agricultural and
Technological Research in Zajecar, Serbia.
In the order to determine the percentage of gliadin per
gram of thirteen different wheat cultivars, gliadin was iso-
lated from flour (0.125–0.250 mesh) by two step 60%
ehanolic extraction (for every sample 0,5 g of wheat flour
was extracted with 5 ml of 60% ethanol with agitation
over night; after that it was centrifuged 10 min on 3000
rpm, supernatant was decanted and 5 ml of 60% ethanol
were added to the pallets once again for 1 hour with agi-BMC Immunology 2009, 10:32 http://www.biomedcentral.com/1471-2172/10/32
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tation; after centrifugation supernatants were collected).
Gliadin content in wheat cultivars' ethanolic extracts, as
well as in the ethanolic exract of crude Sigma, or Fluka
gliadin, after appropriate dilution, was determined
according to manufacturer, by commercial sandwich
ELISA tests, using R5 monoclonal antibody (Ridascreen,
R-Biopharm, Germany), and PWG gliadin as the antigen).
Protein content of investigated wheat was determined
with Kjeldahl method, based on determination of total
nitrogen.
Patients
Fifteen patients with histopathologically confirmed celiac
disease were included in investigation: all of them were
not on gluten-free diet (GFD). Seven had the enhanced
antigliadin IgA and nine patients were with the increased
levels of IgG immunoglobulins, but four out from fifteen
CD patients had no enhanced levels of both anti-gliadin
IgA and IgG antibodies, determined on commercial BS
test.
The group of multiple myeloma patients consisted of six-
teen patients with multiple myeloma, before therapy.
Among them three had the enhanced IgA immunoreactiv-
ity and only one patient had the enhanced concentrations
of anti-gliadin IgG antibodies determined on commercial
BS test.
Informed consent was obtained from each patient and the
Ethics Committee of the Institute of Oncology and Radi-
ology of Serbia (for patients with MM) and Ethics Com-
mittee of the Clinical Center of Serbia (for patients with
CD) approved the study protocol.
After determination of the concentrations of anti-gliadin
IgA and IgG antibodies in tested sera by standard diagnos-
tic ELISA Binding Site test in (IU/ml) according to manu-
facturer instructions, the additional non-commercial
ELISA tests were done. Briefly, wells were coated with 100
μl of ehanolic extracts of gliadin isolated from mentioned
wheat cultivars by two step 60% ehanolic extraction and
standardized to make final quantity of gliadin (5 μg/
wells) by monoclonal antibody R5 (Ridascreen, R-Biop-
harm, Germany). At the same way standardized 60% eth-
anolic extract of crude gliadin from Fluka and crude
gliadin from Sigma Chemicals were used as the antigens,
too. HRP labeled antibodies (Binding Site), were used as
secondary antibodies. Blocker was 1% bovine serum albu-
min (BSA). After blocking, 100 μl of diluted (1:100)
tested sera and one control serum were dispensed in
appropriate wells. During the first incubation, anti-glia-
din antibodies from human serum recognizing the anti-
gen bind to it, while all unbound proteins were removed
by washings. After that, purified peroxidase labeled sheep
anti-human IgA, or IgG conjugates (100 μl) were added,
they attach to the captured human autoantibodies, and
the excess of unbound conjugate was removed by wash-
ings. The optical density (OD) of developed colour was
measured on ELISA reader. Standardization of the results
in repeated ELISA assays was done expressing these OD in
(IU/ml) after the comparison with OD developed after
the reaction of one CD control patients' serum with eth-
anolic extract of gliadin (Sigma) which was present in
every test, and who had high anti-gliadin immunoreactiv-
ity by BS commercial test. Standardization of the results
with control patient's serum in ELISA tests was done sep-
arately for both groups of analyzed patients.
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